Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

The addition of high-dose cytarabine to rituximab/bendamustine (RB) induction could improve outcomes for transplant-eligible patients with mantle cell lymphoma (MCL). We conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of RB and 3 cycles of rituximab/high...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Merryman, Reid W., Edwin, Natasha, Redd, Robert, Bsat, Jad, Chase, Matthew, LaCasce, Ann, Freedman, Arnold, Jacobson, Caron, Fisher, David, Ng, Samuel, Crombie, Jennifer, Kim, Austin, Odejide, Oreofe, Davids, Matthew S., Brown, Jennifer R., Jacene, Heather, Cashen, Amanda, Bartlett, Nancy L., Mehta-Shah, Neha, Ghobadi, Armin, Kahl, Brad, Joyce, Robin, Armand, Philippe, Jacobsen, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065472/
https://ncbi.nlm.nih.gov/pubmed/32126141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001355
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados